Asia-Pacific Roundup: India’s CDSCO halves clinical trial review timelines

@India@s Central Drugs Standard Control Organization (CDSCO) is halving turnaround times for some clinical trial submissions as part of a raft of reforms to the regulation of drug development. The New Drugs and Clinical Trials (Amendment) Rules, 2026 update the original 2019 legislation.Read More